版本:
中国

Allergan plc (AGN.N)

AGN.N ( 纽约证券交易所 )

143.17USD
00:21 BJT
涨跌 (%)

$1.68 (+1.19%)
收盘
$141.49
开盘
$142.08
当日最高
$143.35
当日最低
$140.44
成交量
74,230
平均成交量
683,883
52 周最高
$197.00
52 周最低
$125.84

概况

Allergan plc是一家专业制药公司。 该公司从事品牌药品、医学美容、生物仿制药和非处方药品的开发、制造、营销和分销。该公司通过三个部门运营:美国专业治疗、美国通用医药和国际。 美国专业治疗部门销售与美国品牌相关的产品,包括医学美容、皮肤科产品、眼科护理、神经科学和泌尿科治疗产品。美国通用医药部门包括与美国境内品... (更多)

概况

Beta: 1.17
市值(百万): $69,117.80
已发行股本(百万): 334.31
股息: 0.70
股息收益率 (%): 1.35

财务指标

  AGN.N Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -11.66 -- --
ROI: -3.08 14.23 13.83
ROE: -5.61 15.46 15.25

UPDATE 3-Proxy firms back Allergan in fight against Appaloosa

April 15 Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal that the Botox maker immediately split the roles of chief executive officer and chairman. 全文
04/16 01:58

UPDATE 1-U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

WASHINGTON, April 15 The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe. 全文
04/15 21:46

U.S. Supreme Court rejects Allergan bid to shield drug patents from review

WASHINGTON, April 15 The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe. 全文
04/15 21:36

REFILE-Proxy firms Glass Lewis and ISS back Allergan in fight against Appaloosa

April 15 Allergan Plc said on Monday that proxy advisory firms Institutional Shareholder Services Inc and Glass Lewis & Co had urged its shareholders to vote against hedge fund Appaloosa LP's proposal to immediately separate the drugmaker's chief executive officer and chairman roles. 全文
04/15 20:02

UPDATE 9-Wynn ends A$10 bln acquisition talks with Australia's Crown Resorts

* Wynn shares down 3.2 percent (Adds context on the aborted talks) 全文
04/10 02:15

UPDATE 2-Health Canada plans to suspend Allergan's breast implant license

April 4 Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to the Botox-maker on Thursday. 全文
04/05 04:35

Health Canada plans to suspend Allergan's breast implant license

April 4 The Canadian health regulator said on Thursday it was advising Allergan Plc that it plans to suspend the license for the Botox-maker's Biocell breast implants. 全文
04/05 01:57

BRIEF-Allergan And Molecular Partners Announce Topline Safety Results From Maple Study Of Abicipar Pegol

* ALLERGAN AND MOLECULAR PARTNERS ANNOUNCE TOPLINE SAFETY RESULTS FROM MAPLE STUDY OF ABICIPAR PEGOL 全文
04/02 19:12

UPDATE 1-Hedge fund Appaloosa unimpressed by Allergan board promises

March 25 Activist investor Appaloosa LP said on Monday that Allergan Plc's board was doing "everything except what needs to be done" in a series of concessions the drug company announced last week in response to criticism from the hedge fund. 全文
03/26 05:01

Hedge fund Appaloosa unimpressed by Allergan board promises

March 25 Activist investor Appaloosa LP responded to proposed concessions from the board of Allergan Plc by saying it had done everything "except what needs to be done" and calling on other investors to take further "disruptive" steps to change the company. 全文
03/25 19:53

竞争者

收益 vs. 预测